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Hepatic stellate cellHepatic stellate cell (HSC) activation is a crucial step in the development of liver ﬁbrosis. Peroxisome-proliferator
activated receptor γ (PPARγ) exerts a key role in the inhibition of HSC activation. Leptin reduces PPARγ expres-
sion in HSCs and plays a unique role in promoting liver ﬁbrosis. The present studies aimed to investigate the
mechanisms underlying leptin regulation of PPARγ1 (amajor subtype of PPARγ) in HSCs in vivo and in vitro. Re-
sults revealed a leptin response region inmouse PPARγ1 promoter and indicated that the region included a GATA
binding protein binding site aroundposition−2323. GATAbinding protein-2 (GATA-2) could bind to the site and
inhibit PPARγ1 promoter activity inHSCs. Leptin induced GATA-2 expression inHSCs in vitro and in vivo. GATA-2
mediated leptin inhibition of PPARγ1 expression by its binding site in PPARγ1 promoter inHSCs andGATA-2pro-
moted HSC activation. Leptin upregulated GATA-2 expression through β-catenin and sonic hedgehog pathways
in HSCs. Leptin-induced increase in GATA-2 was accompanied by the decrease in PPARγ expression in HSCs and
by the increase in the activated HSC number and liver ﬁbrosis in vivo. Our data might suggest a possible new ex-
planation for the promotion effect of leptin on liver ﬁbrogenesis.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Liverﬁbrosis is the result of chronic liver injury frommultiple causes.
The ﬁbrogenic response is characterized by progressive accumulation of
extracellular matrix (ECM) which is produced mainly by activated he-
patic stellate cell (HSC) [1]. HSC activation is a crucial step in the devel-
opment of liver ﬁbrosis [1]. The process of HSC activation is the
transdifferentiation from quiescent to myoﬁbroblastic cell and requires
global reprogramming of HSC gene expression which must be orches-
trated by key transcription regulators. Quiescent HSCs aremuch like ad-
ipocyte and HSC activation appears to be analogous to adipocyte to
preadipocyte transdifferentiation [2]. It has been shown that
peroxisome-proliferator activated receptor γ (PPARγ) and sterol regu-
latory element binding protein-1c (SREBP-1c), the transcription factors
(TFs) controlling adipocyte differentiation, play key roles in the inhibi-
tion of HSC activation [2,3]. Overexpression of PPARγ or SREBP-1c
leads to morphologic and biochemical reversals of activated HSCs to
quiescent cells [4].isome-proliferator activatedre-
dgehog; ECM, Extracellularma-
M, Dulbecco's modiﬁed Eagle's
+86 513 85051796.
).Liver ﬁbrosis is shown to be six times more prevalent in obese pa-
tients as compared with general population [5,6] while obese patients
are often accompanied by hyperleptinemia [7,8]. Accumulating evi-
dence demonstrates that leptin, an adipocyte-derived hormone, plays
a unique role in promoting liver ﬁbrosis in vitro and in vivo [9–13].
Therefore, we observed the effect of leptin on PPARγ in HSCs in vitro
and in vivo and showed that leptin evidently reduced PPARγ expression
in HSCs, hence contributing to HSC activation [14,15]. The underlying
mechanisms for leptin inhibition of PPARγ expression in HSCs have
not been fully elucidated. PPARγ include two subtypes, namely
PPARγ1 and PPARγ2, and PPARγ1 is the major subtype of PPARγ in
HSCs [16]. Thus, the present studies were aimed to investigate the
mechanisms underlying leptin regulation of PPARγ1 in HSCs in vitro
and in vivo, mainly focusing on: 1) TFs mediating the effect of leptin
on PPARγ1 expression in HSCs; and 2) the signaling pathways by
which leptin regulates the correlated TFs.
2. Materials and methods
2.1. Materials
Leptin was purchased from ProSpec-Tany TechnoGene (Rehovot,
Israel) and used to treat HSCs in vitro at 100 ng/ml [13], unless other-
wise stated. XAV939 (a speciﬁc inhibitor for β-catenin pathway) and
cyclopamine (a speciﬁc inhibitor for Hedgehog (Hh) signalingpathway)
were purchased from Santa Cruz (CA, USA) and selleck Chemicals
2368 Q. Zhou et al. / Biochimica et Biophysica Acta 1842 (2014) 2367–2377(Houston, USA), respectively. Thioacetamide (TAA)was from Sigma (St.
Louis, MO, USA). Sonic Hedgehog N-terminus (ShhN) was from R&D
Systems (Minneapolis, MN, USA).
2.2. HSC isolation and culture
HSCswere isolated fromadult Kunmingmice (Animal ResearchCen-
ter of Nantong University, Nantong, China) as we described previously
[15]. HSCs between passages 3 and 6 were used for experiments. After
12 h of serum starvation in Dulbecco's modiﬁed Eagle's medium
(DMEM)with 1 % fetal bovine serum (FBS), HSCswere treatedwith lep-
tin, unless otherwise stated.
2.3. Animal studies
C57BL/6J ob/ob mice (leptin-deﬁcient obese mouse, Model Animal
Research Center of Nanjing University, Nanjing, China), 6 week old,
were randomly separated into two groups (six mice/each group). We
adopted a mouse model of TAA-induced liver damage [17]. TAA is usu-
ally used for induction of mouse liver injury [13,17].
The ﬁrst two groups were given the administration of TAA (200 μg/g
bodyweight, two times aweek) or TAA plus leptin (1 μg/g bodyweight,
once per day) by intraperitoneal injection (i.p.) for 4-week [13,17].
The second two groups were treated with Ad.Fc (a control adenovi-
rus encoding IgG2α Fc fragment, a gift from Dr. Jill A. Helms, Stanford
University, USA) or Ad.Dkk1 (adenovirus encoding mouse Dickkopf-1,
2 × 107 pfu/g body weight, once every two weeks, a gift from Dr. Jill
A. Helms) [18] by tail vein throughout the 4-week period of TAA plus
leptin treatment as previously described [13].
The third two groups were treated with cyclopamine (1 μg/g body
weight, once per day) or vehicle by i.p. throughout the 4-week period
of TAA plus leptin treatment.
After 4-week, the livers were ﬁxed in 4% buffered paraformaldehyde
for immunostaining analysis or livers were used for Western blot anal-
ysis andhydroxyprolinedetermination orHSCswere isolated frommice
for Western blot analysis. All the mice were given free access to water
and standard chow diet and received humane care. Experiments were
approved by the Institutional Animal Care and Use Committee of the
University of Nantong (2012-0031).
2.4. Immunoﬂuorescence staining and sirius red staining
Double ﬂuorescence staining was used to examine the expression of
Sonic hedgehog (Shh), β-catenin, GATA binding protein 2 (GATA-2),
and PPARγ in HSCs in the liver as we described previously [13]. Brieﬂy,
paraformaldehyde-ﬁxed liver sectionswere blockedwith normal serum
and incubated with primary antibody against Shh (1:50, Santa Cruz, CA,
USA),β-catenin (1:100, Santa Cruz, CA, USA), GATA-2 (1:50, Santa Cruz,
CA, USA), PPARγ (1:100, Abcam, MA, USA) and primary antibody
against synaptophysin (SYP, 1:10, Abcam, MA, USA), a marker for
quiescent and activated HSCs [19], followed by incubation with
DyLight594-conjugated secondary antibody (1:500, ImmunoReagents,
Inc., Raleigh, USA) and DyLight488-conjugated secondary antibody
(1:500, ImmunoReagents, Inc., Raleigh, USA). For single ﬂuorescence
staining of α-smooth muscle actin (α-SMA) on the liver sections,
paraformaldehyde-ﬁxed liver sections were blocked with normal
serum and incubated with primary antibody against α-SMA (1:100,
Abcam) and subsequently the DyLight594-conjugated secondary anti-
body. The nuclei were counterstained with Hoechst 33342 (Sigma, St.
Louis, MO, USA). The images were captured with the ﬂuorescence mi-
croscope and representative images were shown.
For the analysis of liver ﬁbrosis, sirius red was used to stain collagen
on liver sections. Brieﬂy, paraformaldehyde-ﬁxed liver sections were
stainedwith picric acid-fast green (Amresco, Solon, USA) and then incu-
bated with picric acid–sirius red (Amresco, Solon, USA) for 1 h. Images
were captured with light microscope.2.5. Plasmid constructs and transient transfection assay
To construct PPARγ1 promoter luciferase reporter plasmid, the
mouse PPARγ1 promoter (from−2333 to +157) was ampliﬁed from
genomic DNA of Kunming mice and was inserted into KpnI/XhoI sites
of pGL3-basic (Promega, Madison, USA). This constructed plasmid was
named as pPPARγ1(−2333)Luc. The short PPARγ1 promoter reporter
plasmids were constructed by using pPPARγ1(−2333)Luc and were
named as pPPARγ1 (−1823)Luc (from −1823 to +157), pPPARγ1
(−2245)Luc (from−2245 to +157).
To construct the site-mutated PPARγ1 promoter reporter plasmids,
the potential GATA-2 binding site in PPARγ1 (around the site
of −2323) was mutated by using pPPARγ1(−2333)Luc and KOD-
Plus-Mutagenesis Kit (TOYOBO CO., LTD., Osaka, Japan) according to
the manufacturer's instructions. The plasmid was named as
pPPARγ1(GATA mut) Luc.
To construct luciferase reporter plasmid containing three tandem re-
peats of potential GATA-2 binding site of PPARγ1 promoter, tandem re-
peats of potential GATA-2 binding sitewere synthesized and cloned into
KpnI/XhoI site upstream of SV40 promoter in pGL3-promoter vector
(Promega, Madison, USA). The plasmid was named as p3xGATA-Luc
and the sense of strand DNA was 3 × (5′-tcttttGATAtgtgcaga-3′).
For constructing mouse GATA-2 promoter luciferase reporter plas-
mid, GATA-2 promoter (from−2657 to+118) was ampliﬁed from ge-
nomic DNA of Kunming mice and was inserted into MluI/XhoI sites of
pGL3-basic. The plasmid was named as pGATA2(−2657)Luc.
For constructing plasmid encoding GATA-2 protein, total RNA was
extracted from mouse cultured HSCs by using TRI-Reagent (Sigma, St.
Louis, USA) and reverse transcripted into cDNA. Then, GATA-2 cDNA
was ampliﬁed from total cDNA and cloned into KpnI/XhoI sites of
pcDNA3.1 (Invitrogen, CA, USA). The plasmid was named as pcDNA-
GATA2.
All the primers were used for the construction of the respective
plasmid and for mutation were shown in supplemental data 1. All the
sequences of the constructed plasmids were conﬁrmed by DNA se-
quence analysis.
Plasmid piLentsiRNA-GATA2 (encoding small interfering RNA
targeting mouse GATA-2) and piLentsiRNA-GFP (control) were from
abm (Richmond, BC, Canada).
HSCs in twelve-well plastic plates (unless otherwise stated) were
transiently transfected with the respective plasmid with by using Lipo-
fectAMINE reagent (Life Technologies, New York, USA) according to
manufacturer's instructions. In cells transfected with reporter plasmid,
30 ng of control vector expressing Renilla luciferase (pRL-TK; Promega,
Madison, USA) was cotransfected into the cells. Luciferase activity was
quantiﬁed ﬂuorimetrically by using the Dual-Luciferase Reporter
Assay System (Promega, Madison, USA) and the data were expressed
as the ratios of Photinus to Renilla luciferase activity for normalization
of Photinus luciferase activity.2.6. Western blot analysis
Western blot analyses were conducted as we described previously
[15]. Brieﬂy, target protein was detected by primary antibody against
GATA-2 (1:500, Santa Cruz), PPARγ (1:500, Abcam), α1(I)collagen
(1:2000, Santa Cruz), α-SMA (1:2000, Abcam), Shh (1:500, Santa
Cruz), β-Catenin (1:500, Santa Cruz), transforming growth factor β1
(TGFβ1,1: 500, Santa Cruz), platelet-derived growth factor receptor
β(PDGFRβ, 1:1000), matrix metalloproteinases 1 (MMP1, 1:500,
Abcam), matrix metalloproteinases 2 (MMP2, 1:500, Abcam), tissue in-
hibitor of metalloproteinases 1 (TIMP1, 1:500, Santa Cruz), tissue inhib-
itor of metalloproteinases 2 (TIMP2, 1:500, Santa Cruz), or β-actin
(1:2000, Santa Cruz) and subsequently by horseradish peroxidase-
conjugated secondary antibody (1:4000). β-Actin was used as an inter-
nal control.
Fig. 1. Leptin response elements exist between position−2333 and−2245 upstream of
the transcription start site of PPARγ1 promoter. HSCs were transfected with 1.6 μg of
the respective reporter plasmid containing PPARγ1 promoter of different lengths and
treated with or without leptin for 24 h. Luciferase assays were performed (n = 3).
⁎P b 0.05 vs the control without leptin.
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Total RNA was extracted by using TRI-Reagent (Sigma, St. Louis,
USA) according to the manufacturer's instructions. Real-time PCR was
performed as we described previously [14]. For the analysis of fold
change in mRNA level of target gene relative to the endogenous
cyclophilin control, the Ct values were normalized against cyclophilin
and analyzed by using the ΔΔCt method. The primers for real-time
PCR were shown in supplemental data 1.
2.8. Electrophoretic mobility shift assay (EMSA)
EMSA assays were performed by using LightShift Chemiluminescent
EMSA Kit (Pierce Biotechnology, lL, USA). Brieﬂy, nuclear proteins were
ﬁrstly extracted by NE-PER Nuclear and Cytoplasmic Extraction Re-
agents according to the manufacturer's instructions (Pierce Biotechnol-
ogy, Rockford, lL, USA). Biotinylated DNA fragments (labeled probes)
between−2333 and−2304 (containing the potential GATA-2 binding
site, shown in supplemental data 1) of mouse PPARγ1 promoter was
synthesized by Life Technologies (Shanghai, China) and used for
GATA-2 binding assay. The labeled probes were incubated with 5 μg
protein of nuclear extract in the binding buffer at 25 °C for 20 min. For
the competition assay, 5 μg protein of nuclear extract was preincubated
with 100-fold molar excess of the unlabeled probes before the addition
of the labeled probe. For supershift assay, 5 μg protein of nuclear extract
was preincubated with 1 μg of GATA-2 antibody before the addition of
the labeled probes. The samples were subjected to electrophoresis in a
5% nondenaturating polyacrylamide gel and transferred onto a nylon
membrane and detected by Substrate Working Solution.
2.9. Chromatin immunoprecipitation (ChIP)
ChIP assays were carried out as we described previously [20] by
using Pierce Agarose Chip Kit (Pierce, Rockford, IL, USA). Brieﬂy, cul-
tured HSCs were cross-linked with 1% formaldehyde and the nuclei
from the cells were incubated with Micrococcal Nuclease and lysed.
10% of the digested chromatin was preserved as input control and the
rest of the digested chromatin were incubated with GATA-2 antibody
(Santa Cruz, CA, USA). The puriﬁed DNA from immunoprecipitation
and the input samples were used for the analysis of a fragment
(132 bp) between nucleotides−2362 and−2230 (containing a poten-
tial GATA-2 binding site around −2323) by real-time PCR. The used
primers were shown in supplementary data 1.
According to the method as described by Mastrogiannaki et al. [21],
the ampliﬁcation by real-time PCR was quantiﬁed as the ratio: [2^(Ct
input–Ct ChIP) treatment]/[2^(Ct input–Ct ChIP) without treatment], where
Ct ChIP is the Ct value corresponding to the immunoprecipitated DNA,
and Ct input is the Ct value of an aliquot of digested chromatin sample
before immunoprecipitation.
2.10. Hydroxyproline determination
Hydroxyproline was determined biochemically as described [22]
and the HP content was expressed as μg/g of wet liver.
2.11. Statistical analysis
The results are expressed as mean values ± standard deviation
(S.D.). Differences between means were evaluated using an unpaired
two-sided Student's t-test. Where appropriate, comparisons of multiple
treatment conditions with controls were analyzed by ANOVA with the
Dunnett's test for post hoc analysis. Each result was obtained from at
least three independent differentiation experiments. P value b 0.05 is
considered as signiﬁcant.3. Results
3.1. Leptin response elements exist between position−2333 and−2245
upstream of the transcription start site of PPARγ1 promoter
To identify leptin response elements in PPARγ1 promoter, HSCs
transfected with pPPARγ1(-2333)Luc or pPPARγ1 (−1823)Luc were
treated with or without leptin. Fig. 1A showed that luciferase activity
was reduced in cells with pPPARγ1(−2333)Luc but not pPPARγ1
(−1823) by leptin, suggesting a DNA fragment between −2333 and
−1823 in PPARγ1 promoter contained leptin response elements.
Next, pPPARγ1 (−2245) Luc was used to transfected HSCs and treated
with or without leptin. Fig. 1B showed that leptin failed to affect the lu-
ciferase activity, suggesting that leptin response elements existed be-
tween position−2333 and−2245 in PPARγ1 promoter.
The possible TF binding sites in the DNA fragment (between−2333
and−2245) of PPARγ1 promoter were predicted by software BioBase
(http://www.biobase-international.com/). Some of the possible TF
binding sites including the potential GATA protein binding site (around
position −2323 upstream of the transcription start site) were
underlined (supplemental data 2). PPARγ plays key roles in promoting
adipocyte differentiation [23] and in inhibiting HSC activation [2]. In
contrast, GATA proteins serve as the negative regulators of adipocyte
formation [24,25]. Since leptin treatment reduced PPARγ expression
in HSCs [14,15], it was interesting to investigatewhether GATA proteins
bound to the potential GATA protein binding site in PPARγ1 promoter
and mediated leptin inhibition of PPARγ1 expression in HSCs. As tran-
scriptional factor GATA-2, a member of the GATA protein, is a gatekeep-
er by controlling the transition from preadipocytes to adipocytes [26],
we ﬁrstly hypothesized that GATA-2 might mediate leptin inhibition
of PPARγ1 expression by binding to the potential site in PPARγ1 pro-
moter in HSCs.3.2. GATA-2 inhibits PPARγ1 promoter activity by binding to a site around
position -2323 of PPARγ1 promoter and reduces PPARγ1 expression
To test whether the possible GATA protein binding site (around po-
sition of−2323) affected PPARγ1 promoter activity, the site was mu-
tated by using pPPARγ1(−2333)Luc and the constructed plasmid is
named as pPPARγ1(GATA mut) Luc. HSCs was transfected with
pPPARγ1(−2333)Luc (control) or pPPARγ1(GATA mut) Luc and incu-
bated with leptin. Fig. 2A demonstrated that the mutation of the possi-
ble GATA protein binding site led to the increase in luciferase activity.
This result revealed the inhibitory effect of the site on PPARγ1 promoter
activity in the presence of leptin in HSCs.
For the evaluation of the effects of GATA-2 on PPARγ1 promoter ac-
tivity and transcription activity, HSCs were cotransfected with
pPPARγ1(−2333)Luc plus pcDNA-GATA2 (encodingGATA-2) or vector
Fig. 2. GATA-2 reduces PPARγ1 expression and activity by binding to PPARγ1 promoter. (A, B, C) Transfection assay for analysis of PPARγ1 promoter activity (n = 3). The ﬁrst group of
HSCs was transfected with 1.6 μg of pPPARγ1(-2333)Luc or pPPARγ1(GATA mut) Luc and incubated with leptin for 24 h (A). The second group of HSCs was cotransfected with 0.8 μg of
pPPARγ1(-2333)Luc and 0.8 μg of pcDNA-GATA2 (encoding GATA-2) or control vector and incubated for 24 h (B). The third group of HSCs was cotransfected with 0.8 μg of pPPARγ1(-
2333)Luc plus 0.8 μg of piLentsiRNA-GATA2 or piLentsiRNA-GFP (control) and incubated with leptin for 48 h (C). Luciferase assays were performed. *P b 0.05 vs the cells with
pPPARγ1(−2333)Luc. **P b 0.05 vs the cells with vector. #P b 0.05 vs the cells with piLentsiRNA-GFP. (D) Real-time PCR of PPARγ1 expression and Western blot analyses of PPARγ ex-
pression (n = 3). HSCs in six-well plastic plates were transfected with 3.2 μg of piLentsiRNA-GATA2 or piLentsiRNA-GFP and incubated with leptin for 48 h, PPARγ1 mRNA levels and
PPARγ protein levels were determined respectively by real-time PCR and Western blot analyses. β-Actin was used as an internal control. *P b 0.05 vs the cells with piLentsiRNA-GFP.
(E) Transfection assay for analysis of PPARγ1 promoter activity (n = 3). HSCs was cotransfected with 0.8 μg of pPPARγ1(-2333)Luc or pPPARγ1(GATA mut) Luc plus 0.8 μg of pcDNA-
GATA2 or vector and incubated for 24 h. Luciferase assays were performed. *P b 0.05 vs the cells with pPPARγ1(−2333)Luc plus pcDNA-GATA2. (F) EMSA of the interaction between
GATA-2 and a possible GATA-2 binding site (around position−2323) of PPARγ1 promoter. HSCswere stimulatedwith orwithout leptin for 24 h and nuclear extracts (NE)were prepared.
5 μg of nuclear proteins were incubated with biotinylated DNA fragment (labeled probe containing the potential GATA-2 binding site around−2323). For competition assay, 5 μg of nu-
clear proteins from cells treatedwith leptinwas preincubatedwith 100-foldmolar excess of the unlabeled probe before the addition of labeled probe. For supershift assay, 5 μg of nuclear
proteins from cells treated with leptin was preincubated with 1 μg of anti-GATA2 antibody before the addition of the labeled probe. A representative EMSA was shown from three inde-
pendent experiments. (G) ChIP analysis of the interaction between GATA-2 and the possible GATA-2 binding site (around−2323) of PPARγ1 promoter (n = 3). HSCs were stimulated
with or without leptin for 24 h and ChIP analysis was performed by using anti-GATA2 antibody. A fragment (132 bp) between nucleotides−2362 and−2230 (containing the possible
GATA-2 binding site) in PPARγ1 promoter was examined by real-time PCR. *P b 0.05 vs the cells without leptin. (H) Transfection assay for the analysis of the activity of an artiﬁcial pro-
moter harboring three tandem repeats of the possible GATA-2 binding site in PPARγ1 (n = 3). HSCs were cotransfected with 0.8 μg of p3xGATA-Luc or pGL3-promoter vector (control)
plus 0.8 μg of pcDNA-GATA2 or vector and incubated for 24 h. Luciferase assay was performed. *P b 0.05 vs the cells with pGL3 promoter plus pcDNA-GATA2. (I) Western blot analyses of
the expressions of PPARγ and GATA-2 (n = 3). HSCs isolated from the normal mouse liver (quiescent HSCs,qHSCs) or HSCs cultured for 7 days on a plastic dish (activated HSCs,aHSCs)
were used for Western blot analyses. β-Actin was used as an internal control.
2370 Q. Zhou et al. / Biochimica et Biophysica Acta 1842 (2014) 2367–2377and the result showed that pcDNA-GATA2 signiﬁcantly reduced
PPARγ1 promoter activity (Fig. 2B). Next, HSCs were cotransfected
with pPPARγ1(−2333)Luc plus piLentsiRNA-GATA2 (for knockdown
of GATA-2 expression) or piLentsiRNA-GFP (control) (Fig. 2C) or HSCs
were transfected with piLentsiRNA-GATA2 or piLentsiRNA-GFP
(Fig. 2D). After all the transfected cells were incubated with leptin for
48 h, the luciferase activities (Fig. 2C), PPARγ1 mRNA levels (Fig. 2D),
and PPARγ protein levels (PPARγ1 is the major subtype of PPARγ in
HSCs [16] and PPARγ1 antibody is not available, thus PPARγwas detect-
ed by using PPARγ antibody) (Fig. 2D) were examined. Results indicat-
ed that the knockdown of GATA-2 expression led to the increases in
luciferase activity (Fig. 2C), PPARγ1 mRNA level (Fig. 2D), and PPARγ
protein levels (Fig. 2D). Results in Fig. 2B–D pointed to the inhibitory ef-
fect of GATA-2 on PPARγ1 expression in HSCs.
To test whether GATA-2 functioned by the potential GATA protein
binding site (around −2323), we cotransfected HSCs with pPPARγ1
(−2333)Luc or pPPARγ1(GATA mut) Luc plus pcDNA-GATA2 or vector.
Fig. 2E showed that the inhibitory effect of pcDNA-GATA2 on the lucifer-
ase activity in cells with pPPARγ1(GATA mut) Luc was reduced as com-
pared with that in cells with pPPARγ1(−2333)Luc. These results
suggested that GATA-2 might bind to the site (around −2323) in
PPARγ1 promoter, thus exerting its inhibitory effect on PPARγ1
expression.For detecting the direct interaction of GATA-2 with the possible
GATA-2 binding site, nuclear proteins were extracted from HSCs stimu-
lated with or without leptin and used for EMSA assay. The possible
GATA-2 binding site was used as the probe. Supershift assay (Fig. 2F,
lane 3) and competition assay (Fig. 2F, lane 4) demonstrated that the
site was bound by GATA-2 protein. As compared with the lane 1 (with-
out leptin treatment), lane 2 (with leptin treatment) demonstrated the
increase in the binding of protein to the probe, suggesting that leptin
might promote thebinding of GATA-2 to the probe. For in vivo examina-
tion of the binding of GATA-2 to the probe, HSCs were stimulated
with or without leptin and ChIP assay was performed by using GATA-
2 antibody (Fig. 2G). A DNA fragment (132 base pairs) between nucleo-
tides −2362 and −2230 (containing the potential GATA-2 binding
site) in PPARγ1 promoter was examined by real-time PCR and results
showed that leptin increased GATA-2 binding to the DNA fragment
(Fig. 2G). EMSA and ChIP assays suggested the binding of GATA-2 to
the possible GATA protein binding site around position −2323 in
PPARγ1 promoter.
We also constructed a plasmid p3xGATA-Luc containing three tan-
dem repeats of the potential GATA-2 binding site of PPARγ1 and exam-
ined the effect of GATA-2 on the artiﬁcial promoter. HSCs were
cotransfected with p3xGATA-Luc or pGL3-promoter vector (control)
plus pcDNA-GATA2 or vector (control) (Fig. 2H). Fig. 2H demonstrated
2371Q. Zhou et al. / Biochimica et Biophysica Acta 1842 (2014) 2367–2377that the luciferase activity in cells with p3xGATA-Luc plus pcDNA-
GATA2 signiﬁcantly decreased as compared with that with p3xGATA-
Luc plus vector, which suggested the GATA-2-induced inhibition of
the artiﬁcial promoter activity. This result further conﬁrmed that
GATA-2 bound to the site (around−2323) in PPARγ1, thus inhibiting
PPARγ1 promoter activity.
We also examined the expressions of PPARγ and GATA-2 in quies-
cent HSCs (isolated from normal mouse liver and directly used for
Western blot analysis) and activated HSCs (cultured for 7 days on plas-
tic dish).Western blot analysis showed that, as expected, PPARγ protein
level signiﬁcantly decreased in activated HSCs as compared with that in
quiescentHSCs (Fig. 2I), on the contrary, GATA-2 protein level increased
in activated HSCs as compared with that in quiescent HSCs (Fig. 2I).
These results suggested that the upregulation of GATA-2 was accompa-
niedwith the decline in PPARγ expression during the process of HSC ac-
tivation, which was in line with the effect of GATA-2 on PPARγ
expression in HSCs as shown in Fig. 2A–H.
3.3. Leptin induces GATA-2 expression in HSCs in vitro
Since leptin promoted the binding of GATA-2 to PPARγ1 promoter
(Fig. 2F), we examined the effect of leptin on GATA-2 expression in
HSCs. Fig. 3A indicated that leptin stimulation caused a dose-
dependent increase in GATA-2 protein level. Based on the result, HSCs
were incubated with or without 100 ng/ml of leptin and GATA-2Fig. 3. Leptin stimulates GATA-2 expression and activity. (A, B)Western blot analysis or real-tim
leptin for 24 h. GATA-2 protein levels andmRNA levelswere examined bywestern blot analysis
used as an internal control. *P b 0.05 vs the cells without leptin. (C, D) Transfection assay fo
transfected with 1.6 μg of pGATA2(−2657)Luc (C) or p3xGATA-Luc (D) and incubated with or
leptin. (E) Real-time PCR andWestern blot analyses of α-SMA and α1(I)collagen expressions (
(siGATA-2) or piLentsiRNA-GFP (siGFP, control) and incubated with leptin for 48 h. Real-time
control.mRNA levels were detected. Fig. 3B showed the promotion effect of lep-
tin on GATA-2 expression at transcriptional level. Furtherly, HSCs
transfected with pGATA2(-2657)Luc (containing mouse GATA-2 pro-
moter) were incubated with leptin. Luciferase assay indicated that lep-
tin stimulation led to the increase in the GATA-2 promoter activity
(Fig. 3C), which was in line with the results in Fig. 3A and B. In view of
the fact that GATA-2 bound to the artiﬁcial promoter (containing the
three tandem repeats of GATA-2 binding site) and inhibited its activity
(Fig. 2H), we also detected the effect of leptin on GATA-2 trans-
regulatory activity by using p3xGATA-Luc. HSCs were transfected with
p3xGATA-Luc and then treatedwith or without leptin (Fig. 3D). Lucifer-
ase assay demonstrated that leptin reduced the luciferase activity in
cells with p3xGATA-Luc, suggesting that leptin increased GATA-2
trans-regulatory activity in HSCs.
Taken together, results in Fig. 3A–D strongly suggested the promo-
tion effect of leptin on GATA-2 expression and activity in HSCs in vitro
and, combined with the data in Fig. 2, implied that GATA-2 was a medi-
ator for leptin inhibition of PPARγ1 expression in cultured HSCs.
Leptin has been shown to promote the expressions of α-SMA (a
well-established marker for HSC activation) and α1(I) collagen (the
major component of ECM) in HSCs [11,13] whereas GATA-2 was a me-
diator for leptin inhibition of PPARγ1, a key TF in the inhibition of HSC
activation, in cultured HSCs. Thereby, we investigated the role of
GATA-2 in leptin promotion of the expressions of α-SMA and
α1(I) collagen in cultured HSCs. HSCs were transfected withe PCR analysis of GATA-2 expression (n= 3). HSCs were incubatedwith different doses of
and real-time PCR analysis, respectively. Representative blots were shown and β-actinwas
r analysis of GATA2 promoter activity and trans-regulatory activity (n = 3). HSCs were
without leptin for 24 h. Luciferase activities were examined. *P b 0.05 vs the cells without
n= 3). HSCs in six-well plastic plates were transfected with 3.2 μg of piLentsiRNA-GATA2
PCR and Western blot analyses were performed. *P b 0.05 vs the cells with the respective
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Real-time PCR and Western blot analyses (Fig. 3E) demonstrated that
the knockdown of GATA-2 reduced mRNA and protein levels of α-
SMA and α1(I)collagen, which was in line with the role of GATA-2 in
leptin inhibition of PPARγ1 in HSCs.
3.4. β-Catenin pathway and Hh pathway are involved in leptin-induced in-
creases in GATA-2 expression and activity in cultured HSCs
Bothβ-catenin pathway andHhpathwaywere demonstrated tome-
diate the promotion effect of leptin on HSC activation [11,13] and leptin
induced the expression of GATA-2 which contributed to HSC activation
(Fig. 3). Therefore, there exists a possibility that bothβ-catenin pathway
and Hh pathway might be involved in leptin promotion of GATA-2 ex-
pression in HSCs. To address the possibility, HSCs were pretreated
with or without 5 μM of XAV939 (inhibiting β-catenin pathway) [13]
or 5 μMof cyclopamine (inhibitingHhpathway) [11] before leptin stim-
ulation. Western blot and real-time PCR analyses (Fig. 4A and B)
showed that the interruption of leptin-induced β-catenin pathway or
Hh pathway (leptin + XAV or Cyclo) reduced leptin-induced upregula-
tion of GATA-2 protein and mRNA levels, as compared with the respec-
tive control with leptin alone. Next, Ad.Dkk1 (encoding Dickkopf-1
inhibiting β-catenin pathway) and ShhN (stimulating Shh pathway)Fig. 4. Both β-catenin pathway and Hh pathway mediate leptin-induced increases in GATA-2
expression (n = 3). HSCs were preincubated with or without 5 μM of XAV939 (XAV, inhibiting
stimulation for 24 h. GATA-2 protein levels and mRNA levels were examined by western blot a
and β-actin was used as an internal control. *P b 0.05 vs the respective control with leptin alon
cultured in six-well plastic plates. The ﬁrst group of HSCs (the left panel) was transducted with
bated with leptin for 24 h. The second group of HSCs (the right panel) was incubated with 100
amined by real-time PCR and Western blot analyses. *P b 0.05 vs the cells with the respective
ﬁrst group ofHSCs (the left panel)was transfectedwith 1.6 μg of pGATA2(-2657)Luc and preinc
stimulation for 24 h. The second group of HSCs (themiddle panel) was transductedwith 1.6 μg
leptin for 24 h. The third group of HSCs (the right panel) was transfected with 1.6 μg of pGATA
tivitieswere examined. *P b 0.05 vs the cellswith leptin alone. **P b 0.05 vs the cellswith the resp
3). HSCswere transfectedwith 1.6 μg of p3xGATA-Luc and preincubatedwith orwithout 5 μMof
activities were examined. *P b 0.05 vs the cells with leptin alone.were used to inhibit and stimulate the respective signaling pathway.
As shown in Fig. 4C, HSCs infected with Ad.Dkk1 or Ad.Fc (control)
were incubated with leptin or HSCs were incubated with ShhN or the
vehicle. Real-time PCR and Western blot analyses demonstrated that
the inhibition of β-catenin pathway by Ad.Dkk1 reduced the levels of
GATA-2 mRNA and protein while the stimulation of Shh pathway in-
creased the levels of GATA-2 mRNA and protein (Fig. 4C), which sup-
ported the results in Fig. 4B.
For examining the effect of leptin-induced β-catenin or Hh path-
way on GATA-2 promoter activity, the ﬁrst group of HSCs transfected
with pGATA2(-2657)Luc were preincubated with 5 μM of XAV939 or
5 μM of cyclopamine before leptin stimulation. The second group of
HSCs was transducted with pGATA2(-2657)Luc and Ad.Dkk1 or the
control Ad.Fc and then treated with leptin. The third group of HSCs
was transfected with pGATA2(-2657)Luc and incubated with ShhN
or the vehicle. Luciferase assays indicated that the interruption of
leptin-induced the two signaling pathways by respective inhibitor
(Leptin + XAV or Leptin + Cyclo) reduced leptin-induced luciferase
activity, as compared with cells treated with leptin only (left panel in
Fig. 4D), suggesting that the two pathways induced by leptin increased
GATA-2 promoter activity.Moreover, the inhibition ofβ-catenin signaling
pathway by Ad.Dkk1 also reduced the luciferase activity (middle panel in
Fig. 4D) and stimulation of Shh signaling pathway by ShhN promotedexpression and activity. (A, B) Western blot analysis or real-time PCR analysis of GATA-2
β-catenin pathway) or cyclopamine (Cyclo, inhibiting Hh pathway) for 1 h before leptin
nalysis (A) and real-time PCR analysis (B), respectively. Representative blots were shown
e. (C) Real-time PCR andWestern blot analyses of GATA-2 expression (n= 3). HSCs were
100MOI Ad.Dkk1 (for the inhibition of β-catenin pathway) or the control Ad.Fc and incu-
ng/ml of ShhN or the vehicle for 24 h. The levels of GATA-2 mRNA and protein were ex-
control. (D) Transfection assay for the analysis of GATA-2 promoter activity (n = 3). The
ubatedwith orwithout 5 μMof XAV939 (XAV) or cyclopamine (Cyclo) for 1 h before leptin
of pGATA2(-2657)Luc and 100MOI Ad.Dkk1 or the control Ad.Fc and then incubatedwith
2(-2657)Luc and incubated with 100 ng/ml of ShhN or the vehicle for 24 h. Luciferase ac-
ective control (Ad.Fc or vector). (E) Transfection assay for analysis of GATA-2 activity (n=
XAV939 (XAV) or cyclopamine (Cyclo) for 1 h before leptin stimulation for 24h. Luciferase
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Fig. 4D suggested that the two pathways were also involved in leptin
induction of GATA-2 promoter activity.
Furtherly, the effect of leptin-induced β-catenin or Hh pathway on
GATA-2 trans-regulatory activity was examined by using p3xGATA-
Luc. HSCs were transfected with p3xGATA-Luc and then pretreated
with or without XAV939 or cyclopamine before leptin treatment
(Fig. 4E). As expected, luciferase assay showed that the inhibition of
leptin-induced β-catenin or Hh pathway reduced leptin-induced de-
crease in luciferase activity (Leptin + XAV or Leptin + Cyclo) as com-
pared with the control with leptin alone, suggesting that the two
pathways mediated leptin promotion of GATA-2 trans-regulatory
activity.
The results in Fig. 4 indicated that β-catenin pathway and Hh path-
waymediated leptin-induced increase in GATA-2 expression and activ-
ity in HSCs in vitro.Fig. 5. Leptin stimulates the activation of of β-catenin pathway or Hh pathway, accompanied by
induced liver injury of ob/obmice. Two groups of ob/obmice (6mice/each group)were given th
leptin (1 μg/g bodyweight, once per day) by intraperitoneal injection for 4-week. Doubleﬂuore
or PPARγ-positive HSCs by using the respective primary antibody againstβ-catenin, Shh, GATA-
activated HSCs) and subsequently the DyLight594-conjugated secondary antibody (red ﬂuore
were counterstained with Hoechst 33342 (blue ﬂuorescence). The representative images were
ples of positively stained cells. The total HSCs (SYP-positive HSCs) and β-catenin-, GATA-2-, PP
niﬁcation and the values were expressed as fold changes relative to the respective total HSCs
The values were shown as a histogram on the respective right panel. *P b 0.05.3.5. Leptin induces β-catenin pathway and Hh pathway, accompanied by
the increase in GATA-2 expression and liver ﬁbrosis and the decrease in
PPARγ expression in HSCs in TAA-induced liver injury of ob/ob mice
To examine whether leptin treatment inﬂuences pathways of β-
catenin and Hh and the expressions of GATA-2 and PPARγ in HSCs
in vivo (Because PPARγ1 antibody is not available, PPARγwas detected
by using PPARγ antibody), we examined the expressions of β-catenin,
Shh, GATA-2, and PPARγ in HSCs in TAA-induced liver injury of ob/ob
mice. After the mice were given the administration of TAA plus vehicle
or TAA plus leptin for 4-week, the β-catenin-, Shh-, GATA-2-, or
PPARγ-positive HSCs were detected by double ﬂuorescence staining
or HSCswere isolated from the treatedmice and directly used forWest-
ern blot analysis ofβ-catenin, Shh, GATA-2, or PPARγ. Fig. 5 showed that
the relative number of β-catenin-, Shh-, or GATA-2-positive HSCs in the
livers with TAA plus leptin (T + L) signiﬁcantly increased as comparedthe increase in GATA-2 expression and the decrease in PPARγ expression in HSCs in TAA-
e administration of TAA (200 μg/g bodyweight, two times aweek) plus vehicle or TAAplus
scence staining on the liver sectionwas performed for detecting β-catenin-, Shh-, GATA-2-,
2, or PPARγ plus primary antibody against synaptophysin (SYP, amarker for quiescent and
scence) and DyLight488-conjugated secondary antibody (green ﬂuorescence). The nuclei
captured with the ﬂuorescence microscope. Scale bar 50 μm. Arrowheads indicated exam-
ARγ-, or Shh-positive HSCs were counted in six randomly chosen ﬁelds at 100-fold mag-
(empty column) in group treated with TAA plus vehicle (T) or TAA plus leptin (T + L).
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promoted the expressions of β-catenin, Shh, or GATA-2 in HSCs in the
model of TAA-induced liver injury. Conversely, the relative number of
PPARγ-positive HSCs in the livers with TAA plus leptin signiﬁcantly de-
creased as compared with that in the livers with TAA plus vehicle, indi-
cating that leptin reduced PPARγ expression in HSCs in the samemodel.
Western blot analysis by using HSCs isolated from the treated mice
demonstrated the same results (Fig. 1 of supplemental data 3) as
shownby doubleﬂuorescence staining (Fig. 5).We also detected the ex-
pressions of inducers of liver ﬁbrosis (TGFβ1, PDGFRβ, MMP2, TIMP1,
and TIMP2), inhibitor of liver ﬁbrosis (MMP1), and collagen (shown
by hydroxyproline content) in the respective treated livers (the protein
levels ofα1(I)collagen andα-SMA in the samemodel have been shown
in our previous studies [13]). Western blot analysis showed that leptin
enhanced the expressions of TGFβ1, PDGFRβ, MMP2, TIMP1, TIMP2,
and hydroxyproline content and reducedMMP1 expression in the livers
of mouse model of TAA-induced liver damage (Fig. 1 of supplemental
data 3), which supported the results as shown by double ﬂuorescence
staining in Fig. 5.
These results suggested that leptin-induced activation in β-catenin
pathway or Hh pathway was accompanied by the increase in GATA-2
expression and the decrease in PPARγ expression in HSCs and enhanced
liverﬁbrosis in themousemodel of TAA-induced liver injury. The in vivo
results were in line with in vitro results.3.6. Interruption of leptin-induced β-catenin pathway or Hh pathway leads
to the decrease in GATA-2 expression and the increase in PPARγ expression
in HSCs in TAA-induced liver injury of ob/ob mice, accompanied by the in-
hibitions of HSC activation and liver ﬁbrosis
Furtherly, we used the Ad.Dkk1 or cyclopamine to interrupt the re-
spective signaling pathway induced by leptin in the mouse model of
TAA-induced liver injury as described in Materials and methods and
the expressions of GATA-2 and PPARγ in HSCs (Fig. 6A and B) or the
α-SMA-positive cells in livers were detected by immunoﬂuorescence
analysis (Fig. 6C) or HSCs were isolated from the treated mice and di-
rectly used for Western blot analysis of GATA-2 and PPARγ (Fig. 2 of
supplemental data 3). Liver ﬁbrosis was examined by sirius red staining
(Fig. 6C). Comparedwith the respective control (TAA+ Leptin+ Ad.Fc,
T + L, Fig. 6A) or (TAA + Leptin + Vehicle, T + L, Fig. 6B), the relative
number of GATA-2-positive HSCs signiﬁcantly decreased and the rela-
tive number of PPARγ-positive HSCs increased in the livers with
Ad.Dkk1 (TAA + Leptin + Ad.Dkk1, T + L + Dkk1, Fig. 6A) or
cyclopamine (TAA+ Leptin + Cyclo, T + L+ Cyclo, Fig. 6B). These re-
sults suggested that leptin-induced β-catenin pathway or Hh pathway
led to the increase in GATA-2 expression and the decrease in PPARγ ex-
pression in HSCs in vivo in the model. Western blot analysis by using
HSCs isolated from the treated mice demonstrated the same results
(Fig. 2 of supplemental data 3) as shown by double ﬂuorescence stain-
ing (Fig. 6A and B).
Both the number of α-SMA-positive cells and collagen (shown by
sirius red staining) also decreased in the livers with cyclopamine
(TAA + Leptin + Cyclo, T + L + Cyclo) as compared with its control
without cyclopamine (TAA + Leptin + Vehicle, T + L) (Fig. 6C), which
supported the roles of leptin-induced Hh pathway in the expressions of
GATA-2 and PPARγ in HSCs in themodel. Our previous studies have dem-
onstrated that the interruption of leptin-induced β-catenin pathway by
Ad.Dkk1 in the samemodel reducedα1(I)collagen and the number of ac-
tivated HSCs [13], therefore, we here have not examined them again. We
also detected the expressions of TGFβ1, PDGFRβ, MMP1, MMP2, TIMP1,
TIMP2, and collagen (shown by hydroxyproline content) in the treated
livers. Western blot analysis showed that the interruption of leptin-
induced β-catenin pathway or Hh pathway reduced the expressions of
TGFβ1, PDGFRβ, MMP2, TIMP1, TIMP2, and hydroxyproline content and
enhanced MMP1 expression in the livers of mouse model of TAA-induced liver damage (Fig. 2 of supplemental data 3), which supported
the results as shown by double ﬂuorescence staining in Fig. 6.
4. Discussion
Leptin plays a unique role in promoting liver ﬁbrosis in vitro and
in vivo [9–13] and elicits an inhibitory effect on the expression of
PPARγ, a key TF for inhibiting HSC activation, in HSCs [14,15]. The pres-
ent studies demonstrated the mechanisms by which leptin down-
regulated PPARγ1 in HSCs. Results suggested that: 1) Leptin stimulated
the expression of GATA-2 in vivo and in vitro; 2) GATA-2 could bind to
the PPARγ1 promoter at a site around position−2323 in PPARγ1 pro-
moter and inhibit PPARγ1 promoter activity in vitro; 3)GATA-2mediat-
ed leptin inhibition of PPARγ1 expression by GATA-2 binding site
(around position−2323) of PPARγ1 promoter and GATA-2 promoted
HSC activation in vitro; and 4) leptin up-regulated GATA-2 expression,
at least in part, through β-catenin pathway and Hh pathway in vivo
and in vitro. 5) leptin-induced increase in GATA-2 was accompanied
by the decrease in PPARγ expression in HSCs and by increase in the ac-
tivated HSC number and liver ﬁbrosis in ob/ob mouse model.
PPARγ includes two subtypes, namely PPARγ1 and PPARγ2. The two
subtypes arise from the use of different promoters and alternative splic-
ing [27]. PPARγ1 is the major form of PPARγ in HSCs [16]. Our re-
searches showed that GATA-2 inhibited PPARγ1 expression in HSCs
and identiﬁed a site around position −2323 of PPARγ1 promoter as
GATA-2 binding site. Moreover, the binding site for GATA-2 was one
of leptin response elements in PPARγ1 promoter. These results were
based on multi-level experiments: 1) the progressive 5′-deletion,
point mutation, gain- and loss-of-function of GATA-2, EMSA, and ChIP;
2) leptin-induced increase in GATA-2 expression in vitro and in vivo.
TFs of GATA binding proteins have been found to serve as negative
regulators of adipocyte formation [24,25]. GATA-2, a member of GATA
binding protein family, suppresses adipocyte differentiation [25,26].
More importantly, it traps cells at thepreadipocyte stage and the change
of GATA-2 expression is the early events in the commitment of the
preadipocyte to differentiate [26], suggesting that GATA-2 functions as
a crucial TF in controlling adipocyte differentiation. PPARγ is considered
as the central engine of adipocyte differentiation [28]. Quiescent HSCs
are much like adipocyte and HSC activation is analogous to adipocyte
to preadipocyte transdifferentiation [2]. We here showed the relation-
ship between GATA-2 and PPARγ1 in HSCs.
CCAAT/enhancer bindingα (C/EBPα) is another important TF in pro-
motion of adipocyte differentiation [23] and can also reduce HSC activa-
tion and liver ﬁbrosis [29]. GATA-2 is found to bind to C/EBPα protein
and thus inhibits C/EBPα trans-activation activity in NIH 3T3 cells [30],
which is different from the mechanisms underlying GATA-2 inhibition
of PPARγ1.
Since HSC activation is analogous to adipocyte to preadipocyte
transdifferentiation and GATA-2 can trap cells at the preadipocyte
stage [26], there is a possibility that GATA-2 might play an important
role in controllingHSC activation. Our results demonstrated an inhibito-
ry effect of GATA-2 on the expression of PPARγ1, amajor form of PPARγ
in HSCs and a key TF in inhibiting HSC activation, and showed that
GATA-2 knockdown led to the decreases in the expressions of α-SMA
(a well-established marker for HSC activation) and α1(I) collagen (the
major component of ECM) in HSCs in vitro. Furthermore, leptin-
induced increase in GATA-2 was accompanied by the decrease in
PPARγ expression in HSCs and by increase in the activated HSC number
and liver ﬁbrosis in vivo. These results implied the promotion role of
GATA-2 in leptin-induced mouse liver ﬁbrogenesis.
GATA-3, a member of GATA binding proteins, appears to enhance
the development of pulmonary ﬁbrosis [31]. GATA-6 also mediates the
proﬁbrotic, myoﬁbroblast-like differentiation signal of transforming
growth factor-β1 (TGF-β1) in lung ﬁbroblast [32]. We reported here
that GATA-2 suppressed the expression of PPARγ1, a key TF for
inhibiting HSC activation, and contributed to HSC activation and
Fig. 6. Interruption of leptin-induced the pathway of β-catenin or Hh leads to the decrease in GATA-2 expression and the increase in PPARγ expression in HSCs, accompanied by the in-
hibitions of HSC activation and liver ﬁbrosis in TAA-induced liver injury of ob/obmice. The ﬁrst two groups (ob/ob mice, 6 mice/each group) were treated with Ad.Dkk1 (inhibiting β-ca-
tenin pathway, 2 × 107 pfu/g bodyweight, once every twoweeks) or Ad.Fc (a control adenovirus) throughout the 4-week period of TAAplus leptin treatment (A) as described in Fig. 5. The
second two groupswere treatedwith cyclopamine (Cyclo, inhibiting Hh pathway, 1 μg/g bodyweight, once per day) or vehicle throughout the 4-week period of TAA plus leptin treatment
(B). Double ﬂuorescence staining on the liver section was performed for detecting GATA-2- or PPARγ-positive HSCs as described in Fig. 5. Single ﬂuorescence staining on
the liver sections was used to detect α-SMA by the primary antibody against α-SMA and the DyLight594-conjugated secondary antibody (red ﬂuorescence) or liver ﬁbrosis
was examined by sirius red staining of collagen (C). The nuclei were counterstained with Hoechst 33342 (blue ﬂuorescence). The representative images were captured
with the ﬂuorescence microscope or a light microscope. Scale bar 50 μm. Arrowheads indicated examples of positively stained cells. The total HSCs (SYP-positive HSCs)
and GATA-2- or PPARγ-positive HSCs were counted in six randomly chosen ﬁelds at 100-fold magniﬁcation and the values were expressed as fold changes relative to
the respective total HSCs (empty column) in group treated with TAA + Leptin + Ad.Fc (T + L) (A), TAA + Leptin + Ad.Dkk1 (T + L + Dkk1) (A), TAA + Leptin + Vehicle
(T + L) (B), or TAA + Leptin + Cyclo (T + L + Cyclo) (B). The values were shown as a histogram on the respective right panel (A and B). The α-SMA-positive HSCs were
counted in six randomly chosen ﬁelds at 100-fold magniﬁcation and the average values were shown as a histogram on the right panel (C). *P b 0.05.
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ing proteinsmight be not only involved in adipocyte differentiation, but
are also correlated with organ ﬁbrogenesis.Leptin is an adipocyte-derived hormone and links nutrition, metab-
olism, and immune homeostasis [33,34]. It can suppress lipid synthesis
in preadipocyte [35] and reverse adipocyte differentiation [36]. In this
2376 Q. Zhou et al. / Biochimica et Biophysica Acta 1842 (2014) 2367–2377report, leptin was shown to induce GATA-2 expression in HSCs. Consid-
ering the key role of GATA-2 in controlling adipocyte differentiation, the
inﬂuence of leptin on GATA-2 expression in HSCs seems to be in line
with its inhibitory effect on lipid synthesis and adipocyte differentiation.
In addition to the role of leptin in GATA-2 expression inHSCs, leptin also
induces GATA-4 activation in cardiomyocytes [37]. TGF-β is a key cyto-
kine in the promotion of HSC activation and its signaling pathway can
bemediated by Smad3 [38]. GATA-4, interacting with Smad3, is a cofac-
tor for TGF-β signaling in granulosa cells [39]. Therefore, it is worth test-
ing whether leptin also affects HSCs by GATA-4.
Interestingly, both β-catenin signaling and Hh signaling are demon-
strated to inhibit adipocyte differentiation [40–42] and are also involved
in the promotion of liver ﬁbrosis [11,43,44]. The activation of β-catenin
signaling pathway is required for liver ﬁbrosis [13], pulmonary ﬁbrosis
[45], and skin ﬁbrosis [46]. The severity of liver ﬁbrosis parallels the
level of Hh pathway activity in patients with different types of liver dis-
ease [47]. Hh signaling pathway is suggested as a regulator of adult liver
repair [48]. It should be noted that the two pathways correlate with the
promotion effects of leptin on HSC activation [11,13]. Our results
showed that leptin-induced activation of β-catenin pathway or Hh
pathway promoted GATA-2 expression in HSCs in vitro and in vivo
andGATA-2 could bind to PPARγ1 promoter, thus inhibiting the expres-
sion of PPARγ1, a key TF in the inhibition of HSC activation. Data from
this study might suggest a mechanism underlying the role of the two
pathways in PPARγ expression in HSCs and in rodent liver ﬁbrogenesis.
5. Conclusions
In summary, this report demonstrated that leptin stimulation in-
duced GATA-2 expression by β-catenin signaling pathway and Hh sig-
naling pathway in HSCs and consequently GATA-2 bound to PPARγ1
promoter at site around position−2323, thus inhibiting PPARγ1 ex-
pression. GATA-2 might be correlated with the effects of leptin on HSC
activation and on the mouse liver ﬁbrosis. These results do not exclude
the other mechanisms underlying leptin regulation of PPARγ1 expres-
sion in HSCs. Our data suggest a possible new explanation for the pro-
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